Advitech Reports Positive Study Results

QUEBEC CITY, QuebecAdvitechSolutions presented results from an ongoing open label clinical study during the10th International Psoriasis Symposium, held in Toronto June 10 to 13. Accordingto Advitech, the study was designed to evaluate the safety and efficacy of itsproduct, XP-828La mix of growth factors from whey protein, in psoriasis.

Eleven adults with chronic stable plaque psoriasis received 5g twice daily of XP-828L for 56 days. At the end of the study, seven subjectshad an improvement of their psoriasis condition, with no adverse effectsreported.

The results of this study will help us in positioning theXP-828L as both a safe and effective solution for treating psoriasis, saidRenaud Beauchesne, president and chief executive officer of Advitech(www.advitech.com).